Muramyl tripeptide: An effective immunotherapy in the surgical setting for pediatric abdominal neoplasms

Daleela Getsiv Jarowenko, Scott C. Sigler, Neal R. Pellis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A potential complication of intraperitoneal neoplasms is the occurance of peritoneal metastases. This experiment hypothesizes that resident peritoneal macrophages, activated by muramyl tripeptide (MTP-PE), will destroy peritoneal tumor. MTP-PE is a lipophilic derivative of the myocbacteria cell wall component responsible for induction of cellular immunity and activation of macrophages to a tumoricidal state. A transplantable murine fibrosarcoma, MCA-F was utilized. Murine hosts were challenged intraperitoneally with 5×103 MCA-F cells. Treatment with MTP-PE micelles or liposome-encapsulated MTP-PE was initiated 48 hours prechallenge and on the day of tumor challenge and continued at 72 hour intervals for the subsequent 21 days. Hosts were observed for survival. At 45 days after tumor challenge, all untreated control animals had succumbed to overwhelming neoplastic disease. In contrast, 30% of the mice treated with liposome-encapsulated MTP-PE (P<.05) and 50% of the animals treated with MTP-PE micelles (P<.001) remained alive at 60 days. Followed for 120 days, 20% of MTP-PE micelle treated mice are long-term survivors. These results suggest that control of intraperitoneal seedings may be achieved with MTP-PE when the tumor burden is small.

Original languageEnglish (US)
Pages (from-to)497-500
Number of pages4
JournalJournal of pediatric surgery
Volume22
Issue number6
DOIs
StatePublished - Jun 1987

Fingerprint

Abdominal Neoplasms
Immunotherapy
Micelles
Pediatrics
Liposomes
Neoplasms
Macrophage Activation
Fibrosarcoma
Peritoneal Macrophages
Cellular Structures
Tumor Burden
Cellular Immunity
Cell Wall
Survivors
Neoplasm Metastasis
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{dd95458bb159450cb22c03e22e4fe885,
title = "Muramyl tripeptide: An effective immunotherapy in the surgical setting for pediatric abdominal neoplasms",
abstract = "A potential complication of intraperitoneal neoplasms is the occurance of peritoneal metastases. This experiment hypothesizes that resident peritoneal macrophages, activated by muramyl tripeptide (MTP-PE), will destroy peritoneal tumor. MTP-PE is a lipophilic derivative of the myocbacteria cell wall component responsible for induction of cellular immunity and activation of macrophages to a tumoricidal state. A transplantable murine fibrosarcoma, MCA-F was utilized. Murine hosts were challenged intraperitoneally with 5×103 MCA-F cells. Treatment with MTP-PE micelles or liposome-encapsulated MTP-PE was initiated 48 hours prechallenge and on the day of tumor challenge and continued at 72 hour intervals for the subsequent 21 days. Hosts were observed for survival. At 45 days after tumor challenge, all untreated control animals had succumbed to overwhelming neoplastic disease. In contrast, 30{\%} of the mice treated with liposome-encapsulated MTP-PE (P<.05) and 50{\%} of the animals treated with MTP-PE micelles (P<.001) remained alive at 60 days. Followed for 120 days, 20{\%} of MTP-PE micelle treated mice are long-term survivors. These results suggest that control of intraperitoneal seedings may be achieved with MTP-PE when the tumor burden is small.",
author = "Jarowenko, {Daleela Getsiv} and Sigler, {Scott C.} and Pellis, {Neal R.}",
year = "1987",
month = "6",
doi = "10.1016/S0022-3468(87)80204-X",
language = "English (US)",
volume = "22",
pages = "497--500",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Muramyl tripeptide : An effective immunotherapy in the surgical setting for pediatric abdominal neoplasms. / Jarowenko, Daleela Getsiv; Sigler, Scott C.; Pellis, Neal R.

In: Journal of pediatric surgery, Vol. 22, No. 6, 06.1987, p. 497-500.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Muramyl tripeptide

T2 - An effective immunotherapy in the surgical setting for pediatric abdominal neoplasms

AU - Jarowenko, Daleela Getsiv

AU - Sigler, Scott C.

AU - Pellis, Neal R.

PY - 1987/6

Y1 - 1987/6

N2 - A potential complication of intraperitoneal neoplasms is the occurance of peritoneal metastases. This experiment hypothesizes that resident peritoneal macrophages, activated by muramyl tripeptide (MTP-PE), will destroy peritoneal tumor. MTP-PE is a lipophilic derivative of the myocbacteria cell wall component responsible for induction of cellular immunity and activation of macrophages to a tumoricidal state. A transplantable murine fibrosarcoma, MCA-F was utilized. Murine hosts were challenged intraperitoneally with 5×103 MCA-F cells. Treatment with MTP-PE micelles or liposome-encapsulated MTP-PE was initiated 48 hours prechallenge and on the day of tumor challenge and continued at 72 hour intervals for the subsequent 21 days. Hosts were observed for survival. At 45 days after tumor challenge, all untreated control animals had succumbed to overwhelming neoplastic disease. In contrast, 30% of the mice treated with liposome-encapsulated MTP-PE (P<.05) and 50% of the animals treated with MTP-PE micelles (P<.001) remained alive at 60 days. Followed for 120 days, 20% of MTP-PE micelle treated mice are long-term survivors. These results suggest that control of intraperitoneal seedings may be achieved with MTP-PE when the tumor burden is small.

AB - A potential complication of intraperitoneal neoplasms is the occurance of peritoneal metastases. This experiment hypothesizes that resident peritoneal macrophages, activated by muramyl tripeptide (MTP-PE), will destroy peritoneal tumor. MTP-PE is a lipophilic derivative of the myocbacteria cell wall component responsible for induction of cellular immunity and activation of macrophages to a tumoricidal state. A transplantable murine fibrosarcoma, MCA-F was utilized. Murine hosts were challenged intraperitoneally with 5×103 MCA-F cells. Treatment with MTP-PE micelles or liposome-encapsulated MTP-PE was initiated 48 hours prechallenge and on the day of tumor challenge and continued at 72 hour intervals for the subsequent 21 days. Hosts were observed for survival. At 45 days after tumor challenge, all untreated control animals had succumbed to overwhelming neoplastic disease. In contrast, 30% of the mice treated with liposome-encapsulated MTP-PE (P<.05) and 50% of the animals treated with MTP-PE micelles (P<.001) remained alive at 60 days. Followed for 120 days, 20% of MTP-PE micelle treated mice are long-term survivors. These results suggest that control of intraperitoneal seedings may be achieved with MTP-PE when the tumor burden is small.

UR - http://www.scopus.com/inward/record.url?scp=0023177489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023177489&partnerID=8YFLogxK

U2 - 10.1016/S0022-3468(87)80204-X

DO - 10.1016/S0022-3468(87)80204-X

M3 - Article

C2 - 3612438

AN - SCOPUS:0023177489

VL - 22

SP - 497

EP - 500

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 6

ER -